Prediction Case File
YouTubeTracking Live

I Sold $CRWV After the Breakout. Here’s Where I’m Buying Back In

1 extracted signal · 0 resolved · 1 still active

Traders Helping Traders profile imageTraders Helping TradersIndependent analyst profile
Source published
01 Sept 2026, 21:58 UTC
Recorded by Tahlil Plus
02 Sept 2026, 00:06 UTC
Video preview for I Sold $CRWV After the Breakout. Here’s Where I’m Buying Back In
Source overview

AI-generated source summary

The analysis focuses on CRWV, a stock, utilizing weekly and daily charts. The presenter identifies a short-term bearish trend, evidenced by lower highs and a 30% price drop over 20 days, originating from a previous high at $180-$200. The current price is $81.85. A key

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Tracking Live
Signals
1
Extracted from this source
Open
1
Still being tracked
Successful
0
Resolved successfully
Failed
0
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
0 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  3. Market predictions extracted

    1 eligible signal linked to this case.

  4. Source processing completed

    Source analysis and structured extraction completed.

  5. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  6. Live evaluation in progress

    1 signal remains active.

Analyst snapshot

Traders Helping Traders

Platform-wide history, separate from this source evaluation.

Reliability
48.8
Tracked signals
83
Historical success
37.0%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail